X0306 4 2015-05-13 0000882796 BIOCRYST PHARMACEUTICALS INC BCRX 0001230708 STAAB THOMAS R II 4505 EMPEROR BLVD. SUITE 200 DURHAM NC 27703 1 Senior Vice President and CFO Emp. Stock Option (Right to Buy) 5.45 2015-05-13 4 A 0 17000 0 A 2015-05-13 2023-08-08 Common Stock 17000 17000 D On May 13, 2015, BioCryst Pharmaceuticals, Inc. initiated a Phase 1 clinical trial to evaluate the safety, pharmacokinetics and pharmacodynamics of orally-administered BCX7353 in healthy volunteers. As a result, one of the vesting criteria associated with the performance-based stock options awarded to all employees in August 2013 has been met. Therefore, 25% of the performance-based stock options vested on May 13, 2015. /s/ Alane P. Barnes, by power of attorney 2015-06-16